The coincident issue of two quality-risk-management-driven
draft guidance documents by the United States Food and Drug
Administration (FDA) and the European Medicines Agency (EMA)
in August 2011 has been considered by many stakeholders and observers
as a paradigm shift in clinical quality risk ...